{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:39:16Z","timestamp":1761129556878},"reference-count":0,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1997,4,1]],"date-time":"1997-04-01T00:00:00Z","timestamp":859852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1997,4]]},"abstract":"<jats:p>The agar dilution MIC method was used to test activities of ticarcillin, ticarcillin-clavulanate, amoxicillin, amoxicillin-clavulanate, ampicillin, ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, inhibitors alone, ceftazidime, and imipenem against 237 Acinetobacter genospecies. A total of 93.2% of strains were beta-lactamase positive by the chromogenic cephalosporin method. Overall, ampicillin-sulbactam was the most active combination against all strains (MIC at which 50% of the isolates are inhibited [MIC50] and MIC90, 4.0 and 32.0 microg\/ml; 86.9% susceptible at &lt; or = 16 microg\/ml), followed by ticarcillin-clavulanate (16.0 and 128.0 microg\/ml; 85.7% susceptible at &lt; or = 64 microg\/ml), piperacillin-tazobactam (16.0 and 128.0 microg\/ml; 84.8% susceptible at &lt; or = 64 microg\/ml), and amoxicillin-clavulanate (16.0 and 64.0 microg\/ml; 54.4% susceptible at &lt; or =16 microg\/ml). Ceftazidime and imipenem yielded MIC50s and MIC90s of 8.0 and 64.0 microg\/ml (ceftazidime) and 0.5 and 1.0 microg\/ml (imipenem), respectively; 71.3% of strains were susceptible to ceftazidime at &lt; or = 16 microg\/ml, and 99.2% were susceptible to imipenem at &lt; or = 8 microg\/ml. Sulbactam was the most active beta-lactamase inhibitor alone (MIC50 and MIC90, 2.0 and 16.0 microg\/ml); clavulanate and tazobactam were less active (16.0 and 32.0 microg\/ml for both compounds). Enhancement of beta-lactams by beta-lactamase inhibitors was not always seen in beta-lactamase-positive strains, and activity of combinations such as ampicillin-sulbactam was due to the inhibitor alone. Acinetobacter baumannii was the most resistant genospecies. By contrast, Acinetobacter haemolyticus, Acinetobacter calcoaceticus, Acinetobacter johnsonii, Acinetobacter junii, Acinetobacter radioresistens, and other non-Acinetobacter baumannii strains were more susceptible to all compounds tested. E-test MICs were within 1 dilution of agar dilution MICs in 38.4 to 89.6% of cases and within 2 dilutions in 61.6 to 98.6% of cases.<\/jats:p>","DOI":"10.1128\/aac.41.4.767","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:28:23Z","timestamp":1539044903000},"page":"767-770","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods"],"prefix":"10.1128","volume":"41","author":[{"given":"M A","family":"Visalli","sequence":"first","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T D","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F A","family":"Renzi","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P C","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.4.767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.4.767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:11:32Z","timestamp":1645474292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.41.4.767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["10.1128\/AAC.41.4.767"],"URL":"https:\/\/doi.org\/10.1128\/aac.41.4.767","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,4]]},"assertion":[{"value":"1997-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}